Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...
Blog Post
August 22, 2023
A recent, thought-provoking blog by our colleague, Justin Sandefur, titled “How Economists got Africa’s AIDS Epidemic Wrong”, has sparked a debate about the historical role of cost-effectiveness analysis in assessing the investments of the President's Emergency Plan for AIDS Relief (PEPFAR) and, imp...
Blog Post
February 20, 2023
On Sunday February 19th, the 36th Assembly of Heads of State and Government of the African Union elected Dr Jean Kaseya, a public health physician from the Democratic Republic of Congo, as the new Director General of the Africa Centres for Disease Control and Prevention (Africa CDC). Dr Kaseya will ...
Blog Post
December 14, 2022
It’s clear that COVID-19 oral antivirals are effective, and recent deals have made them even cheaper for African countries. But should these countries be investing in these medicines? Or would spending on alternative health services be better value for money? Unfortunately, there is very little avai...
Blog Post
November 10, 2022
Laboratories are a fundamental component of health systems, critical in routine and emergency contexts for both disease surveillance and health services for communicable and non-communicable diseases. Investing in laboratories helps countries to create integrated and resilient health systems, achiev...
Blog Post
April 28, 2022
In the past two years, we have all learned that the end of a COVID-19 wave is the end of a chapter, not the end of the story. Ongoing COVID transmission means the risk of new variants of pandemic potential is ever present and vaccination remains our best defence. The primary near-term challenges for...